Employees: 5,722
Size Luyan Pharma (002788.SZ) is a China Consumer Staples company (Drugstore Chains) with a market value of $514M, the 3629th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.92 on 18 Nov 2026.
Performance Over six months the shares fell 32.5%, against -4.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 15 in its peer set.
Growth Revenue grew 3.1% over the last twelve months (peer median +6.5%); the operating margin is 2.6% (peer median 4.3%).
Valuation It trades at 0.4× enterprise value to sales against a peer median of 0.8× (4th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.3 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥21.6B | CN¥21.2B | CN¥20.4B | CN¥19.8B | CN¥19.4B |
| Revenue growth | — | +4% | +3% | +2% | — |
| Gross profit | CN¥1.50B | CN¥1.34B | CN¥1.37B | CN¥1.36B | CN¥1.37B |
| EBITDA | n/a | CN¥720M | CN¥821M | CN¥823M | CN¥809M |
| Net income | CN¥274M | CN¥281M | CN¥346M | CN¥364M | CN¥345M |
| Free cash flow | CN¥307M | CN¥455M | CN¥216M | CN¥780M | -CN¥95.3M |
| Capital expenditure | CN¥185M | CN¥234M | CN¥361M | CN¥529M | CN¥328M |
| Total debt | CN¥6.61B | CN¥6.96B | CN¥6.58B | CN¥5.95B | CN¥6.05B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002788.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.0% | -1.0% | 7th lowest of 15 |
| 6-month return | -32.5% | -4.5% | 4th lowest of 15 |
| Distance from 52-week high | -68.5% | -35.5% | lowest of 15 |
| Revenue growth (TTM) | +3.1% | +6.5% | 7th lowest of 15 |
| Operating margin | 2.6% | 4.3% | 6th lowest of 15 |
| EV / Sales | 0.4× | 0.8× | 4th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -0.4% | -7.0% | 5th most demanding of 13 |
| Growth delivered (Del g) | +6.5% | +11.1% | 4th lowest of 13 |
| Hurdle (Req g minus delivered) | -6.8 pp | -20.0 pp | 5th most demanding of 13 |
| ROIC minus cost of capital | +0.3 pp | +2.6 pp | 6th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Luyan Pharma 002788.SZ | China | $514M | -32% | +3% | 3% | 0.4× | -0.4% | +6.5% |
| Beijing Konruns Pharmaceutical 603590.SS | China | $558M | -33% | -1% | 17% | 4.2× | 12.4% | +2.7% |
| Qol 3034.T | Japan | $561M | +26% | +5% | 6% | 0.4× | -16.6% | +12.4% |
| Cawachi 2664.T | Japan | $562M | +31% | -1% | 2% | 0.2× | -6.1% | 0.0% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $701M | -11% | +9% | 2% | 0.8× | 1.1% | +17.4% |
| Genky DrugStores 9267.T | Japan | $728M | +3% | +8% | 5% | 0.6× | n/a | n/a |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $745M | -32% | +15% | 8% | 1.1× | -7.5% | +23.3% |
| Landfar Bio-medicine 000504.SZ | China | $351M | -22% | +497% | -2% | 3.1× | n/a | n/a |
| MedPlus Health Services MEDPLUS.NS | India | $771M | -36% | +21% | 4% | 1.1× | 18.6% | +17.6% |
| Shanghai No. 1 Pharmacy 600833.SS | China | $299M | -22% | +1% | -1% | 0.9× | 19.5% | +6.1% |
| JZJ Chain Drugstore Corporation 605266.SS | China | $293M | -35% | -5% | 0% | 0.7× | -9.9% | +14.8% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.16B | +4% | -2% | 3% | 0.5× | -16.0% | +6.5% |
| Ain 9627.T | Japan | $1.25B | +2% | +42% | 4% | 0.5× | -6.5% | +16.9% |
| Create SD 3148.T | Japan | $1.32B | +3% | +9% | 5% | 0.3× | -11.5% | +8.0% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.71B | +13% | +3% | 5% | 0.8× | -10.7% | +9.7% |